Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2927 · 1 trial · 1 indication
Change in LAERP from before IP infusion to 1st and 2nd assessments during IP infusion
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | A single dose of AZD2927 administered as an iv infusion |
| 2 | PLACEBO_COMPARATOR | A single dose of placebo administered as an iv infusion |
| Name | Type | Description |
|---|---|---|
| AZD2927 | DRUG | A single dose of AZD2927 administered as an iv infusion |
| Placebo | DRUG | A single dose of placebo administered as an iv infusion |
Inclusion Criteria: * male or postmenopausal female, aged 20 to 80 years inclusive, * clinical indication for catheter ablation of atrial flutter, * history of paroxysmal atrial flutter, with or without paroxysmal AF. Single episodes of persistent atrial flutter or AF requiring cardioversion do not...
AZD2927 is an investigational small molecule developed by AstraZeneca PLC for arrhythmia, a cardiovascular condition involving abnormal heart rhythm. It has been studied in a Phase 2 clinical trial. AZD2927 is not described as approved and remains in clinical development.
AZD2927 is being developed for the treatment of arrhythmia, a cardiovascular condition characterized by abnormal electrical activity in the heart. Its only recorded clinical study enrolled patients with arrhythmia and assessed effects on the electrical activity of the heart.
AZD2927 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the Phase 2 study of AZD2927 in arrhythmia conducted in Norway and Sweden.
AZD2927 is in Phase 2 clinical development. One Phase 2 trial has been completed, and no active trials are currently recorded. The drug is investigational and has not been described as approved by the FDA or any other regulatory agency.
AZD2927 has been evaluated in one completed Phase 2 trial, NCT01396226, titled a multi-centre study comparing the effects of AZD2927 and placebo on the electrical activity in the heart in patients. The trial enrolled 20 patients with arrhythmia across Norway and Sweden and was randomized, double-blind, and placebo-controlled.